National's $604m Pharmac promise and how it would pay for it
National would put a further $604 million into Pharmac's medicines budget if it is re-elected.
Leader Christopher Luxon and Health Minister Simeon Brown announced the medicines and screening policy at a private hospital in Epsom, Auckland, according to reports published on 5 October, with funding to come from savings in foreign aid and an extension of free cancer screening RNZ. The package links two votes. Savings outside the Pacific pay for spending in health.
National said it would largely pay for the increase by reducing foreign aid and associated administration costs by 10 percent, while fully protecting aid to the Pacific. It said it would reduce aid outside the Pacific and make the Ministry of Foreign Affairs and Trade more efficient to fund more medicines. Pharmac is the agency that buys medicines for the public system, through what is called the Combined Pharmaceutical Budget. The party costed the total proposal at $823.8 million, including $41.5 million in capital spending for one-off items such as equipment. A $431.2 million reduction in foreign aid spending would offset the cost, the party said. That leaves a $351.1 million net impact on operating budgets, the day-to-day spending.
The screening commitments set specific dates. National promised to lower the free bowel screening age to 50 by 2029. It promised to complete the free breast screening extension to age 74 by 2029. It promised to launch new screening pilots for prostate and lung cancer. It promised free cervical screening for all women aged 25 to 69 from March 2027.
The bowel screening pledge follows earlier moves. National had previously lowered the bowel screening age from 60 to 58 and then to 56, the party said. The new commitment would take eligibility to 50 by the end of the next term if implemented on schedule.
Other elements sit alongside medicines and screening. National promised to establish the Healthy Kiwis Programme offering active prescriptions. It promised to set a national target for clinical trials in New Zealand. It promised to unlock CAR-T cell therapy, a treatment that uses a patient's own immune cells.
The party describes the announcement as a continuation. It says its $604 million boost to Pharmac delivered 66 additional medicines, including 33 new cancer medicines. It welcomed Pharmac's decision to fund three cancer treatments with patient access from 1 June 2025. It welcomed Pharmac's change expanding funded paediatric-origin cancer medicines to give young people fairer, timelier access. National's newsroom carried the pitch as 'More medicines for Kiwis at home', attributed to Brown. The party said a re-elected National Government "will put New Zealand patients first by bringing money back from overseas to fund more medicines."
The broader context here is implementation and fiscal treatment rather than intent. For people who follow the Beehive and health closely, the questions are familiar. How a 10 percent aid and administration reduction is phased across baselines, how the Pacific ringfence is defined in appropriations, and how much of the foreign ministry efficiency is administrative overhead rather than programmes. Whether the $604 million is a straight uplift to the Combined Pharmaceutical Budget or a broader medicines appropriation. How the capital component is timed. Whether screening staff, laboratory capacity and follow-up colonoscopy and treatment can absorb lower age thresholds and wider eligibility by 2029 and from March 2027. Those details will decide the speed of access. The announcement sets the direction. The Budget documents and Pharmac's funding decisions would set the pace.
